All In MedTech

Device Trial Radar · NCT03724539

Optimizing PharmacoTherapy In the Multimorbid Elderly in Primary CAre: the OPTICA Trial

Optimizing PharmacoTherapy In the Multimorbid Elderly in Primary CAre: a Cluster Randomized Controlled Trial (the OPTICA Trial)

Last checked: Nov 20, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Jan 7, 2019

Primary completion

Feb 15, 2021

Study completion Feb 15, 2021

Sponsor

Lead sponsor
University of BernAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Utrecht University; University of Basel; University of Zurich; Swiss National Science Foundation
First posted
Oct 30, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Health services research
FDA-regulated device
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this randomized controlled trial (RCT) is to evaluate whether the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), put into practice through the STRIP Assistant (STRIPA) and implemented by general practitioners (GPs), will lead to an improvement in clinical and economic outcomes in patients aged 65 or older with multimorbidity and polypharmacy.

Conditions

  • Multimorbidity
  • Polypharmacy

Interventions

  • STRIPA interventionDevice

    STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients. Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices.

  • Sham interventionOther

    Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients' medication appropriateness, as measured by two complementary co-primary outcomes: Co-primary outcome #1: change in the Medication Appropriateness Index (MAI)Time frame: 12 months
  2. Patients' medication appropriateness, as measured by two complementary co-primary outcomes: Co-primary outcome #2: change in the Assessment of Underutilization (AOU)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Berner Institut für Hausarztmedizin, BIHAM

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.